Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Outcome measures
Parameter No.
No. of Pipelines 
    1 255 (77.5%)
    2 52 (15.8%)
    ≥3 22 (6.7%)
Platelet function test 
    Yes 316 (96%)
    No 13 (4%)
Clopidogrel responder 
    Yes 228 (72.2%)
    No 88 (27.8%)
Nonresponders' treatment 
    Switch to ticagrelor 27 (30.7%)
    Clopidogrel boost 39 (44.3%)
    Same dose of clopidogrel 22 (25%)
Last angiographic follow-up (median) (range) (mo) 13.5 (1–83)
Follow-up occlusion rate 
    Complete (100%) 297 (78.2%)
    Near-complete (90%–99%) 29 (7.6%)
    Partial (<90%) 54 (14.2%)
Retreatment 
    Endovascular 24 (6.3%)
Posttreatment mRS 
    0–2 314 (95.6%)
    3–5 11 (3.3%)
    6 (Death) 4 (1.2%)
Follow-up mRS 
    Improved 110 (33.4%)
    No change 190 (57.8%)
    Worsened 29 (8.8%)
Neurologic complications 
    Thromboembolic 31 (9.4%)
        Symptomatic 17 (5.2%)
    Hemorrhagic 11 (3.3%)
        Symptomatic 6 (1.8%)

Parameter	No.
No. of Pipelines
1	255 (77.5%)
2	52 (15.8%)
≥3	22 (6.7%)
Platelet function test
Yes	316 (96%)
No	13 (4%)
Clopidogrel responder
Yes	228 (72.2%)
No	88 (27.8%)
Nonresponders' treatment
Switch to ticagrelor	27 (30.7%)
Clopidogrel boost	39 (44.3%)
Same dose of clopidogrel	22 (25%)
Last angiographic follow-up (median) (range) (mo)	13.5 (1–83)
Follow-up occlusion rate
Complete (100%)	297 (78.2%)
Near-complete (90%–99%)	29 (7.6%)
Partial (<90%)	54 (14.2%)
Retreatment
Endovascular	24 (6.3%)
Posttreatment mRS
0–2	314 (95.6%)
3–5	11 (3.3%)
6 (Death)	4 (1.2%)
Follow-up mRS
Improved	110 (33.4%)
No change	190 (57.8%)
Worsened	29 (8.8%)
Neurologic complications
Thromboembolic	31 (9.4%)
Symptomatic	17 (5.2%)
Hemorrhagic	11 (3.3%)
Symptomatic	6 (1.8%)